ClinicalTrials.gg
Active, not recruitingNCT07342114Updated Sep 30, 2026

A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 1 interventional study of RO7875913 and Placebo in Healthy Volunteers, Relapsed Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Genentech, Inc.. Active, not recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Multiple Myeloma by Hoffmann-La Roche — 6 open to participants now, 12 under way, 1 of them phase 3. Multiple Myeloma · Hoffmann-La Roche.

Planned enrollment
4th of 29
240 · median 90
Started
2026
with 3 others
Phase 1
18 of 30
3 open now
Primary completion
2030-06
later than 9 of 11 live
Registered
27th of 30
by date

Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, this one is the 4th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 9 of the 11 other live ones, and was the 27th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 30 studies in Multiple Myeloma by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Multiple Myeloma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.

Part B: The purpose of Part B of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RO7875913 administered in combination with the T cell-engaging bispecific antibody (TCB) cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).

03

Conditions studied

  • Healthy Volunteers
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General:

  • Agreement to adhere to the requirements

Part A:

  • Body weight > 40 kilogram (kg) with a of 18-30 kg per meter square (kg/m\^2)

Part B:

  • (ECOG) Performance Status of 0 or 1
  • of at least 12 weeks
  • Agreement to provide bone marrow and aspirate samples

Exclusion criteria

Exclusion Criteria:

General:

  • Treatment with any vaccine within 4 weeks prior to initiation of study drug, or vaccination scheduled to occur during the study
  • History or current cardiovascular or pulmonary disease that may limit the ability to respond to systemic infusion/injection reactions
  • Positive test result for surface antigen, virus (HCV), or (HIV) antibody screen
  • History of any
  • Major surgical procedure within 28 days prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders
  • Known allergy or to any component of the RO7875913 formulation

Part A:

  • Treatment with biologic therapy (or blinded comparator) within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
  • Treatment with investigational non-biologic therapy (or blinded comparator) within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
  • Clinically apparent or familial history of disease

Part B:

  • Treatment with any systemic chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment
  • Treatment with any medication within 2 weeks prior to first dose of study treatment
  • Absolute plasma cell count exceeding 500/mL or 5% of the peripheral blood white cells
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Part A: RO7875913

    Participants will receive RO7875913.

    Drug: RO7875913

  • Placebo comparator
    Part A: Placebo

    Participants will receive placebo.

    Drug: Placebo

  • Experimental
    Part B: RO7875913 with cevostamab

    Participants will recieve RO7875913 with cevostamab.

    Drug: RO7875913 · Drug: Cevostamab

Interventions

  • DrugRO7875913

    Participants will receive RO7875913 as per the schedule described in the protocol.

  • DrugPlacebo

    Participants will receive placebo as per the schedule described in the protocol.

  • Participants will receive cevostamab as per the schedule described in the protocol

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 3 months

  2. Part B: Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Part A: Serum concentration of RO7875913

    Time frame: Up to Day 76

  2. Part A: Percentage of Participants with Anti-Drug Antibodies (ADAs) to RO7875913 at Baseline and with ADAs to RO7875913 During the Treatment Period

    Time frame: Baseline, Up to Day 76

  3. Part A: Recommended Phase II Dose (RP2D) of RO7875913

    Time frame: Up to approximately 3 months

  4. Part A: Observed Value of Pharmacodynamic Markers

    Time frame: Baseline, up to approximately 3 months

  5. Part B: Serum Concentration of RO7875913

    Time frame: Up to approximately 2 years

  6. Part B: Serum Concentration of Cevostamab

    Time frame: Up to approximately 2 years

  7. Part B: Objective Response Rate

    Time frame: Up to approximately 2 years

  8. Part B: Rate of Complete Response (CR)/ stringent Complete Response (sCR)

    Time frame: Up to approximately 2 years

  9. Part B: Rate of Very Good Partial Response (VGPR) or Better

    Time frame: Up to approximately 2 years

  10. Part B: Duration of Response

    Time frame: Up to approximately 2 years

  11. Part B: Time to First Response

    Time frame: Up to approximately 2 years

  12. Part B: Time to Best Response

    Time frame: Up to approximately 2 years

  13. Part B: Percentage of Participants with Anti-Drug Antibodies (ADAs) to RO7875913 at Baseline and with ADAs to RO7875913 During the Treatment Period

    Time frame: Up to approximately 2 years

  14. Part B: Percentage of Participants with Anti-Drug Antibodies (ADAs) to Cevostamab at Baseline and with ADAs to RO7875913 During the Treatment Period

    Time frame: Up to approximately 2 years

  15. Part B: RP2D of the RO7875913 and Cevostamab Combination Regimen

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 51 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 15, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Jun 17, 2030
CompletionEst.
Jun 17, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participnats WithParticipants With Relapsed/Refractory Multiple Myeloma
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Title A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participnats WithParticipants With Relapsed/Refractory Multiple Myeloma

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07342114
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Mar 11, 2026
Primary completion
Jun 17, 2030 (estimated)
Completion
Jun 17, 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion